Abstract
The model of simian immunodeficiency virus (SIV) infection in rhesus macaques was used to evaluate the effects of recombinant human interferon alpha, Hu IFN-alpha 2b and Hu IFN-gamma B,D, at two doses. Administration began 1 day prior to infection and was continued for 90 days postinfection. Both interferons suppressed SIV antigenemia during the treatment period. Following treatment animals were monitored for 4 years for rate of disease progression. Neither IFN prolonged the asymptomatic period or survival.
MeSH terms
-
Animals
-
Antigens, Viral / blood
-
Biopterins / analogs & derivatives
-
Biopterins / blood
-
CD4 Lymphocyte Count
-
Gene Products, gag / blood
-
Gene Products, gag / immunology
-
Humans
-
Interferon Type I / administration & dosage
-
Interferon Type I / pharmacology*
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / pharmacology*
-
Macaca mulatta
-
Neopterin
-
Recombinant Proteins
-
Simian Acquired Immunodeficiency Syndrome / immunology
-
Simian Acquired Immunodeficiency Syndrome / therapy*
-
Simian Acquired Immunodeficiency Syndrome / virology
-
Simian Immunodeficiency Virus / immunology
-
Time Factors
Substances
-
Antigens, Viral
-
Gag protein p27, Simian immunodeficiency virus
-
Gene Products, gag
-
Interferon Type I
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Biopterins
-
Neopterin